Objective: To investigate the efficacy and safety of an iris-claw phakic intraocular lens (ICPIOL) implantation for high myopia.
Methods: A consecutive group of 25 eyes in 13 patients with -7.88 to -22.88 diopters (D) of myopia was implanted with the Verisyse ICPIOL (AMO), and was examined preoperatively and 1, 7 days, 1, 3, 6, and 12 months postoperatively. Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), manifest refraction, intraocular pressure, and complications were evaluated.
Results: The implantation was successful in all of 25 eyes. Compared with preoperative data, UCVA, BCVA, and spherical equivalent (SE) were improved significantly. At 12-month postoperatively, UCVA was 0.5 or better in all eyes, in which the UCVA in 71.43% eyes was 0.8 or higher; No loss of BCVA was found, 2 lines of BCVA improvement was obtained in 95.24% of patients with ICPIOL, and 1 line BCVA improvement was seen in 4.76% of patients; the power of refraction in all eyes implanted with ICPIOL was stabilized within the variation of +/- 0.50D (71.43%), and +/- 1.00D (85.71%). The corneal endothelial loss was insignificant. No severe complications occurred.
Conclusions: At short-term follow-up, the implantation of the ICPIOL proved to be safe and effective for the correction of myopia in phakic eyes. However, longer follow-up with larger numbers of patients is necessary to evaluate long-term complications.